We are live on ! Find out more
SAGE

Sage Therapeutics

Delisted

SAGE was delisted on the 30th of July, 2025.

197 hedge funds and large institutions have $411M invested in Sage Therapeutics in 2025 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 51 increasing their positions, 53 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

57% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 37

48% more capital invested

Capital invested by funds: $278M → $411M (+$133M)

12% more funds holding

Funds holding: 176197 (+21)

0.42% more ownership

Funds ownership: 83.74%84.15% (+0.42%)

4% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 53

20% less call options, than puts

Call options by funds: $2.1M | Put options by funds: $2.63M

Holders
197
Holders Change
+21
Holders Change %
+11.93%
% of All Funds
2.64%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
58
Increased
51
Reduced
53
Closed
37
Calls
$2.1M
Puts
$2.63M
Net Calls
-$526K
Net Calls Change
-$2.17M

SAGE Hedge Fund Activity: Q1 2025 in Review

197 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2025, worth a combined $411M — up 48% from $278M a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new SAGE positions and 37 closed out — a net gain of 21 holders — while 51 added to existing stakes and 53 trimmed.

The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $32.8M. The largest seller was Fidelity Investments, cutting an estimated $30.1M.

  • 197 institutional investors held Sage Therapeutics (SAGE) as of Q1 2025, up from 176 in Q4 2024.
  • Funds reported $411M of Sage Therapeutics stock for Q1 2025, up 48% quarter-over-quarter.
  • 58 funds opened new Sage Therapeutics positions in Q1 2025 and 37 closed out, a net change of +21 holders.
  • The largest Sage Therapeutics buyer in Q1 2025 was Madison Avenue Partners, an estimated $32.8M added.
  • The largest Sage Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $30.1M sold.

Based on aggregated 13F filings for Q1 2025.